The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2025 | The emerging role of targeted therapies in relapsed mesothelioma
Dean Fennell, University of Leicester, Leicester, UK, comments on the findings of studies on rucaparib in relapsed mesothelioma, noting that the results are promising. Tumor-intrinsic signal, mediated by interferon α signaling, which is not coming from immune cells outside the cancer itself is attributed to its success. These observations may also apply to other PARP inhibitors, including five others that have been studied. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
